|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 9/20 | (2006.01) |
| A61K 9/2054 | (2013.01) | ||
| A61K 31/47 | (2006.01) | ||
| A61K 31/47 | (2013.01) | ||
| A61K 31/194 | (2006.01) | ||
| A61K 31/194 | (2013.01) | ||
| A61P 35/00 | (2006.01) | ||
| A61P 35/00 | (2018.01) |
| (11) | Number of the document | 2981263 |
| (13) | Kind of document | T |
| (96) | European patent application number | 14724909.8 |
| Date of filing the European patent application | 2014-04-04 | |
| (97) | Date of publication of the European application | 2016-02-10 |
| (45) | Date of publication and mention of the grant of the patent | 2022-06-29 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2014/033016 |
| Date | 2014-04-04 |
| (87) | Number | WO 2014/165786 |
| Date | 2014-10-09 |
| (30) | Number | Date | Country code |
| 201361808511 P | 2013-04-04 | US |
| (72) |
WEITZMAN, Aaron , US
|
| (73) |
Exelixis, Inc. ,
1851 Harbor Bay Parkway, Alameda, CA 94502,
US
|
| (54) | CABOZANTINIB DOSAGE FORM AND USE IN THE TREATMENT OF CANCER |
| CABOZANTINIB DOSAGE FORM AND USE IN THE TREATMENT OF CANCER |